

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Multiple Technology Appraisal (MTA)

## Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)

## Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• AbbVie (adalimumab)</li> <li>• Celltrion Healthcare (infliximab)</li> <li>• Hospira UK (infliximab)</li> <li>• Merck Sharp and Dohme (golimumab, infliximab)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• Black Health Agency</li> <li>• Bladder and Bowel Foundation</li> <li>• Bowel Cancer UK</li> <li>• Colostomy Association</li> <li>• Crohn's and Colitis UK</li> <li>• Equalities National Council</li> <li>• GUT Trust</li> <li>• Ileostomy and Internal Pouch Support Group</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• National Association for Colitis and Crohn's Disease (NACC)</li> <li>• Ostomy Lifestyle</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Ulcerative Colitis UK</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Coloproctology of Great Britain and Ireland</li> <li>• British Association for Services to the Elderly</li> <li>• British Geriatrics Society</li> <li>• British Society of Gastroenterology</li> <li>• British Society of Paediatric Gastroenterology, Hepatology and Nutrition</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Possible comparator manufacturers</u></p> <ul style="list-style-type: none"> <li>• Actavis (azathioprine, prednisolone, sulfasalazine)</li> <li>• Alliance Pharmaceuticals (prednisolone)</li> <li>• Almirall (balsalazide)</li> <li>• Aspen (azathioprine, mercaptopurine)</li> <li>• Chiesi (beclomethasone)</li> <li>• Dr. Falk Pharma (budesonide, mesalazine)</li> <li>• Ferring Pharmaceuticals (mesalazine)</li> <li>• Meda Pharmaceuticals (hydrocortisone)</li> <li>• Mylan (azathioprine, sulfasalazine)</li> <li>• Pfizer (sulfasalazine)</li> <li>• Ranbaxy (sulfasalazine)</li> <li>• Relonchem Ltd (azathioprine)</li> <li>• Rosemont Pharmaceuticals</li> </ul>

National Institute for Health and Care Excellence

Matrix for the technology appraisal of infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)

Issue date: November 2013

Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Primary Care Society for Gastroenterology</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• United Kingdom Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS England</li> <li>• NHS South Eastern Hampshire CCG</li> <li>• NHS South Kent Coast CCG</li> <li>• Welsh Government</li> </ul>	<p>(sulfasalazine)</p> <ul style="list-style-type: none"> <li>• Sandoz Ltd (azathioprine, mesalazine)</li> <li>• Shire Pharmaceuticals (mesalazine)</li> <li>• Teva UK Ltd (azathioprine, mesalazine, sulfasalazine)</li> <li>• Tillotts Pharma (mesalazine)</li> <li>• UCB Pharma (olsalazine)</li> <li>• Warner Chilcott (mesalazine)</li> <li>• Winthrop Pharmaceuticals (prednisolone)</li> <li>• Zentiva (prednisolone)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group</li> <li>• CORE (Digestive Disorders Foundation)</li> <li>• Crohn's in Childhood Research Association (CICRA)</li> <li>• Health Research Authority</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• Research Institute for the Care of Older People</li> </ul> <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> <li>• School of Health &amp; Related Research University Sheffield, (SchARR)</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline groups</u></p> <ul style="list-style-type: none"> <li>• National Clinical Guidelines Centre</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales NHS</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

### **MTA Definitions:**

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

#### Assessment group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.